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Abstract
Background and aims: Agreement between measurements of creatinine concentra-
tions using point-of-care (POC) devices and measurements conducted in a standard
central laboratory is unclear for pediatric patients. Our objectives were (a) to assess
the agreement for pediatric patients and (b) to compare the incidence of postopera-
tive acute kidney injury (AKI) according to the two methods.
Methods: This retrospective, single-center study included patients under 18 years of
age who underwent cardiac surgery and who were admitted into the pediatric inten-
sive care unit of a tertiary teaching hospital (Okayama University Hospital, Japan)
from 2013 to 2017. The primary objective was to assess the correlation and the
agreement between measurements of creatinine concentrations by a Radiometer
blood gas analyzer (Cregas) and those conducted in a central laboratory (Crelab). The
secondary objective was to compare the incidence of postoperative AKI between the
two methods based on Kidney Disease Improving Global Outcomes (KDIGO) criteria.
Results: We analyzed the results of 1404 paired creatinine measurements from
498 patients, whose median age was 14 months old (interquartile range [IQR] 3, 49).
The Pearson correlation coefficient of Cregas vs Crelab was 0.968 (95% confidence
interval [CI], 0.965-0.972, P < 0.001). The median bias between Cregas and Crelab
was 0.02 (IQR -0.02, 0.05) mg/dL. While 199 patients (40.0%) were diagnosed as hav-
ing postoperative AKI based on Crelab, 357 patients (71.7%) were diagnosed as having
postoperative AKI based on Cregas (Kappa = 0.39, 95% CI, 0.33-0.46). In a subgroup
analysis of patients whose Cregas and Crelab were measured within 1 hour, similar per-
centage of patients were diagnosed as having postoperative AKI based on Cregas and
Crelab (42.8% vs 46.0%; Kappa = 0.76, 95% CI, 0.68-0.84).
Conclusion: There was an excellent correlation between Cregas and Crelab in pediatric
patients. Although more patients were diagnosed as having postoperative AKI based
on Cregas than based on Crelab, paired measurements with a short time gap showed
good agreement on AKI diagnosis.
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1 | INTRODUCTION
Point-of-care (POC) creatinine devices are capable of providing a
quantitative estimation of a patient's serum creatinine concentra-
tion.1 POC devices, including blood gas analyzers2,3, deliver quick
results compared with a standard central laboratory, saving time and
providing easy access to information to clinicians, especially in inten-
sive care unit (ICU) settings. Some of the blood gas analyzers cur-
rently on the market can provide information on not only creatinine
concentration but also biochemical, hematological, and acid-base
parameters.2,3 The creatinine sensor used in a Radiometer blood gas
analyzer (ABL 800, Radiometer Co, Copenhagen, Denmark) follows
the international recommendations by the National Kidney Disease
Education Program (NKDEP) Laboratory Working Group4 and has
been shown to be a whole blood creatinine measurement method
with calibration traceability to an isotope dilution mass spectometry
(IDMS) standard.3
Plasma creatinine concentration is proportional to the muscle vol-
ume, and the values at different time points soon after birth have dif-
ferent reference intervals compared with those in adults.5
Furthermore, the required volume of a blood sample for a blood gas
analyzer is only of 0.2 to 0.3 mL for neonates, which might cause
errors in measurements. While some studies have shown good agree-
ment between creatinine measurements using a POC device and mea-
surements conducted in a central laboratory,1-3 there have been no
studies in which the agreement between measurements of serum cre-
atinine concentrations by a POC analyzer and those conducted in a
standard laboratory have been assessed for teenage or younger
patients.
The rapid simultaneous measurements of creatinine, electrolytes,
and acid-base parameters using a blood gas analyzer enable quick
treatment and could change clinical practice, especially in a critically ill
setting. We hypothesized that there had been more frequent creati-
nine measurements by a POC device in our pediatric intensive care
unit (PICU) for postoperative patients than measurements in the cen-
tral laboratory due to the easy access to the machine and the large
range of information that can be obtained by a POC blood gas ana-
lyzer. Since worldwide guidelines such as Kidney Disease Improving
Global Outcomes (KDIGO) consensus criteria6 do not mention appro-
priate frequency of creatinine measurements for diagnosis of postop-
erative acute kidney injury (AKI),6 numerous studies assessing
postoperative AKI have adopted their own frequency of creatinine
measurements within certain period of time after surgery.7-10 If there
are indeed more measurements by a POC device, these might provide
additional opportunities to detect pathological changes in serum creat-
inine concentration, potentially improving the detection of AKI. In this
sense, pediatric cardiac patients would be a good population in which
to test this, because of the reported high incidence of postoperative
AKI, especially after the use of cardiopulmonary bypass (CPB).11 Our
objectives were (a) to assess the correlation and the agreement
between measurements of serum creatinine concentrations by a blood
gas machine and those conducted in a central laboratory for pediatric
patients and (b) to compare the incidence of postoperative AKI after
cardiac surgery according to serum creatinine measurements by the
POC device to that based on serum creatinine measurements in the
central laboratory.
2 | MATERIALS AND METHODS
2.1 | Design
We conducted a single-center, retrospective study that was approved
by the Okayama University Hospital Ethics Committee. The commit-
tee waived the need for informed consent for studies involving the
use of the hospital's database. All regulations and measures of ethics
and confidentiality were handled in accordance with the Declaration
of Helsinki.
2.2 | Study population
This was a retrospective study of patients who underwent cardiac sur-
gery with CPB in a tertiary teaching hospital (Okayama University
Hospital, Japan) and were admitted to the PICU in the hospital during
the period from December 2013 to January 2017. We included
patients who were 18 years of age or younger and who were admitted
to the PICU for the first time. Patients without data for initial and/or
postoperative serum creatinine concentrations for the first 48 hours
were excluded.
2.3 | POC creatinine testing and laboratory
measurements
Blood samples were collected in standard prepared, heparinized blood
gas syringes, and measurements were conducted without delay using
a blood gas analyzer (ABL 800, 13B2X00079000003, Radiometer Co,
Copenhagen, Denmark). The analyzer measured whole blood samples
at 37C. The laboratory in the hospital complies with standards of the
National Association of Testing Authorities. The measurement of cre-
atinine concentration by the blood gas analyzer (Cregas) is based on an
enzymatic method, which uses an amperometric biosensor based on
enzymatic conversion.12 During the study period, blood gas analyses
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were performed at the discretion of intensivists or trained nursing
staff in the PICU.
Perioperative serum creatinine concentration was also measured
in a central laboratory (Crelab). Blood samples were taken for labora-
tory analysis, sent to the laboratory within 30 minutes, and analyzed
immediately. Creatinine measurement by the central laboratory is
based on an enzymatic method (BM8040, CA-Z13055TIJ, Japan Elec-
tron Optics Laboratory, Tokyo, Japan). The time of each analysis was
recorded on our electronic medical chart.
2.4 | Primary and secondary objectives
The primary objective was the correlation and the agreement between
Cregas and Crelab. Paired creatinine concentrations of Cregas and Crelab
during a 5-day period after surgery for which the timings of the two
measurements were the closest, and the time gap of their measure-
ments was within 1 hour, considering recommended time gap of the
two measurements from the same blood sample in our institution,
were investigated. The secondary objective was the agreement
between the incidence of postoperative AKI based on Cregas and the
incidence of postoperative AKI based on Crelab during the first
48 hours after surgery. AKI was diagnosed and classified by KDIGO
criteria.6 According to this classification and staging system of AKI,
serum creatinine concentration greater than or equal to 1.5 times the
baseline or increase in serum creatinine greater than or equal to 0.3
mg/dL from the baseline creatinine concentration (both within
48 hours after surgery) constitutes “stage 1”; serum creatinine concen-
tration greater than or equal to 2.0 times the baseline constitutes
“stage 2”; and serum creatinine concentration greater than or equal to
3.0 times the baseline or initiation of renal replacement therapy con-
stitutes “stage 3.”
2.5 | Statistical analysis
Data are presented as n (percentages) or median (interquartile range
[IQR]; 25% quartile, 75% quartile) as appropriate. The correlations
between the two determination methods (Cregas vs Crelab) were
assessed by Pearson correlation coefficients (r) with 95% confidence
interval (CI) and by linear regression. The linear regression is presented
as a scatter plot, regression equation, and correlation coefficient. An
issue of nonindependence from repeated measurements was solved
by averaging the repeated measures data for each participant in sensi-
tivity analyses. Additionally, the agreement between the two methods
was analyzed, and Bland-Altman plots were made to visualize the
agreement. The Bland-Altman plot shows the deviation between the
two methods with different Crelab concentrations. The agreement
between the two methods on the diagnosis of AKI was analyzed by
the Kappa statistic. The baseline creatinine level and postoperative
Cregas and Crelab were investigated among patients with a discordant
AKI diagnosis to understand their characteristics. In order to assess
the agreement between the two methods with the same number of
measurements and with a short time gap, a subgroup analysis was per-
formed for patients who had both Cregas and Crelab where the time
gap between the measurements was within 1 hour. All statistical tests
were two-sided, and the significance level was defined as a P value of
less than.05. All statistical analyses were performed using R 3.6.0
(R foundation for Statistical Computing, Vienna, Austria).
3 | RESULTS
3.1 | Comparison of serum creatinine
concentration measured by the blood gas analyzer and
that measured in the central laboratory
A total of 556 patients were considered for the study. Fifty-eight
patients without data for initial and/or postoperative serum creatinine
concentrations were excluded, and thus, a total of 498 patients were
included in the study. The median age was 14 (IQR 3, 49) months, and
there were 266 males (53.4%). There were 1404 paired creatinine
measurements of Cregas and Crelab, with the median time gap being
25 (IQR 11, 42) minutes. The Pearson correlation coefficient of Cregas
vs Crelab was 0.968 (95% CI, 0.965-0.972, P < 0.001). Figure 1 shows
the results of the linear regression analysis between Cregas and Crelab,
with the following relationship: Cregas = 1.021 × Crelab + 0.010. After
averaging the repeated measures data for each participant, the Pear-
son correlation coefficient of Cregas vs Crelab was 0.975 (95% CI,
0.971-0.979), and the linear regression analysis between Cregas and
F IGURE 1 Scatter plots, regression analysis, and correlation
coefficients for creatinine measurements between the blood gas
analyzer and central laboratory. The result of the linear regression
analysis shows the relationship: Cregas = 1.021 × Crelab + 0.010.
Abbreviations: Cregas, creatinine measuements by blood gas analyzer;
Crelab, creaninine measurements conducted in central laboratory
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Crelab was Cregas = 1.025 × Crelab + 0.010. A Bland-Altman plot of
Cregas vs Crelab is shown in Figure 2. The median bias between Cregas
and Crelab was 0.02 (IQR -0.02, 0.05) mg/dL. The 95% limit of agree-
ment was -0.137 to 0.178 mg/dL.
3.2 | Evaluation of the impact of POC testing on
the diagnosis of AKI
A total of 1439 creatinine measurements were conducted in the
central laboratory within 48 hours after surgery, which meant the
median number of creatinine measurements in the central laboratory
was 3 (IQR 3, 3) per patient during the postoperative period.
According to the KDIGO criteria based on Crelab, among the
498 patients, 199 patients (40.0%) were diagnosed as having post-
operative AKI. On the other hand, a total of 10 799 creatinine mea-
surements were conducted using the blood gas analyzer, which
meant the median number of creatinine measurements by the POC
device was 21 (IQR 17, 26) per patient during the same period.
Based on Cregas, among the 498 patients, 357 patients (71.7%) were
diagnosed as having postoperative AKI. While 161 patients who
were diagnosed as having AKI based on Cregas were not diagnosed
with AKI according to Crelab, only three patients who were diag-
nosed with AKI based on Crelab were not diagnosed with AKI
according to Cregas (Kappa = 0.39, 95% CI, 0.33-0.46). The AKI diag-
nosis based on the two methods is summarized in Table 1. Among
patients with a discordant AKI diagnosis, the median baseline
creatinine level was 0.29 (0.25, 0.36) mg/dL, and the median differ-
ence between the maximum Cregas and the maximum Crelab within
120 hours after surgery was 0.11 (0.08, 0.15) mg/dL.
In a subgroup analysis, there were 250 patients who had both
Cregas and Crelab for the first 48 hours after surgery where the time
gap between the measurements was within 1 hour. The median age
was 14 (IQR 3, 49) months, and there were 142 males (56.8%). Among
those patients, 107 patients (42.8%) were diagnosed as having post-
operative AKI based on Crelab. On the other hand, based on Cregas,
among the 250 patients, 115 patients (46.0%) were diagnosed as hav-
ing postoperative AKI. While 19 patients who were diagnosed as hav-
ing AKI based on Cregas were not diagnosed with AKI according to
Crelab, 11 patients who were diagnosed with AKI based on Crelab were
not diagnosed with AKI according to Cregas (Kappa = 0.76, 95% CI,
0.68-0.84). AKI diagnosis based on the two methods is summarized in
Table 2.
4 | DISCUSSION
4.1 | Key findings
We found an excellent correlation between Cregas and Crelab for
measuring creatinine, with r = .968 (95% CI, 0.965-0.972, P <
0.001) and median bias of 0.02 (IQR -0.02, 0.05) mg/dL. The 95%
limit of agreement was -0.137 to 0.178 mg/dL in this group of
pediatric patients (younger than 18 years of age). Serum creatinine
was measured about seven times more frequently with the blood
F IGURE 2 Bland-Altman plot for the differences between blood
gas analyzer serum creatinine and central laboratory serum creatinine.
The 95% limit of agreement was −0.137 to 0.178
mg/dL. Abbreviations: Cregas, creatinine measurements by blood gas
analyzer; Crelab, creaninine measurements conducted in central
laboratory
TABLE 1 AKI diagnosis based on creatinine measurements by
blood gas analyzer and by those conducted in central laboratory
among all of pediatric patients in the cohort (N = 498)
Central Laboratory
AKI (+) AKI (−)
Blood gas analyzer AKI (+) 196 161 357
AKI (−) 3 138 141
199 299 498
Abbreviations: AKI, acute kidney injury.
TABLE 2 AKI diagnosis based on creatinine measurements by
blood gas analyzer and by those conducted in central laboratory
among patients who had both Cregas and Crelab where the time gap
between the measurements was within 1 h (N = 250)
Central Laboratory
AKI (+) AKI (−)
Blood gas analyzer AKI (+) 96 19 115
AKI (−) 11 124 135
107 143 250
Abbreviations: AKI, acute kidney injury; Cregas, creatinine measurements
by blood gas analyzer; Crelab, creaninine measurements conducted in
central laboratory.
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gas analyzer after cardiac surgery than in the central laboratory.
Despite the excellent agreement between the two methods, using
Cregas and Crelab, a discordant diagnosis of AKI was found in
164 patients (32.9%) (Kappa = 0.39, 95% CI, 0.33-0.46). About
70% of the patients were diagnosed as having AKI based on Cregas
and that percentage was about two times higher than the percent-
age of patients diagnosed as having AKI based on Crelab. In a sub-
group analysis of patients whose Cregas and Crelab were measured
within 1 hour, similar percentage of patients were diagnosed as
having postoperative AKI based on Cregas and Crelab (42.8% vs
46.0%; Kappa = 0.76, 95% CI, 0.68-0.84).
4.2 | Comparison with prior studies
There have been five previous studies in which the accuracy and/or
the precision of POC devices for estimation of creatinine using Radi-
ometer ABL have been assessed. In a retrospective study conducted
on 650 samples from 122 critically ill patients, the accuracy of mea-
surements by the Radiometer was assessed by comparing them with
standard clinical laboratory measurements, and it was shown that the
POC measurements correlated well with central pathology results (r2
= 0.991, P < 0.001).13 Bloomed et al prospectively assessed a total of
183 pairs of samples for creatinine from 207 patients and showed that
the mean difference was +0.018 mg/dL and that the 95% limit of
agreement2 was -0.18 to 0.21 mg/dL. In another prospective cohort
study, of 250 samples from 82 critically ill patients, the mean differ-
ence between serum creatinine measured by a central laboratory and
that measured by POC testing was +0.11 mg/dL (95% limits of agree-
ment: -0.13 to +0.34 mg/dL).14 Skurup et al also measured creatinine
concentrations, in a total of 104 serum samples, and assessed the per-
formance of the creatinine sensor of an ABL blood gas analyzer.3 They
found excellent agreement of POC creatinine assays with laboratory
creatinine assays using IDMS calibration. While our study was the first
to assess the accuracy of measurements by this POC device exclu-
sively for patients younger than 18 years of age, our results are consis-
tent with those of previous studies, showing acceptable agreement
between creatinine measurements by a blood gas analyzer and by lab-
oratory assays.
The impact of POC creatinine testing on clinical practice, how-
ever, is unclear. Although the shortened average time to diagnosis has
been evaluated by using various POC devices in some studies,15,16
there has been no study on the impact of measurements of creatinine
by a blood gas analyzer, especially on the detection of AKI in patients.
We showed that at our hospital, the frequency of creatinine concen-
tration measurements by a POC analyzer was about seven times
higher than that of creatinine concentrations measurements in a cen-
tral laboratory. In addition, we found that the number of patients diag-
nosed as having AKI by Cregas was about two times greater than the
number of patients diagnosed as having AKI by Crelab, and discordant
diagnosis of AKI was found in around one-third of patients regardless
of the good agreement between the two methods for creatinine con-
centration determination.
4.3 | Interpretation
According to the US Clinical Laboratory Improvement Amendments
(USCLIA), the criteria for acceptable performance of measurements is
the target value ±0.3 mg/dL for creatinine.17 We demonstrated high
levels of agreement, with a low median difference of Cregas and Crelab
and 95% limit of agreement within the range specified by the USCLIA.
Our study, which is the first one to assess the performance of a POC
device exclusively on patients younger than 18 years of age, supports
the clinical usefulness of Cregas for patients with a wide range of ages,
when taken together with the results of the other studies
mentioned above.
The reason for serum creatinine being measured much more fre-
quently by the POC device than in the central laboratory might be
related to the immediate availability of the results.15,16 Clinicians
might use the POC device due to the ease of access in clinical practice.
The blood gas data obtained by the analyzer, in addition to that on
creatinine levels, could be another reason for the high frequency of
measurements. Clinicians might perform more POC tests in order to
check the acid-base status for each patient rather than to check
Cregas. Additional studies are needed to understand clinicians' prefer-
ences and choices regarding the use of POC devices for creatinine
measurements.
Despite the excellent agreement between the two methods and
the potential advantage of easy access and frequent information by
the POC device, we need careful discussion before using the POC
device frequently for diagnosis of AKI based on KDIGO criteria for
pediatric patients because of the discordant diagnosis of AKI between
the two methods, as shown in our study. There are several possible
explanations for more patients being diagnosed with AKI based on
Cregas than based on Crelab and the frequent discordant diagnosis of
AKI despite good correlation between the two methods. One possibil-
ity is superior detection of increased creatinine concentration by mul-
tiple Cregas measurements. The more frequently creatinine is
measured, the more possible it becomes for measurement to show the
timing of creatinine increase. The average number of creatinine mea-
surements in the central laboratory was only three per patient within
48 hours after surgery, which was only one-seventh of the average
number of measurements by the blood gas analyzer. This means that
Crelab might miss the chance for detecting a postoperative increase in
creatinine concentration.
A second possible explanation for the discordant diagnosis of AKI
despite good correlation between the two methods is due to a poten-
tial error of each Cregas measurement. Although our study showed a
high level of agreement of Cregas, we could still see some differences
between Cregas and Crelab, as shown in Figure 1. In addition, although
the reported precision of the Radiometer ABL is relatively high,1,3
there is a risk of obtaining incorrect creatinine concentration when
the concentrations are measured many times by a blood gas analyzer.
Increased risk of errors due to multiple measurements of Cregas could
be one reason. Furthermore, low creatinine concentration in pediatric
patients should also be considered in the discordant diagnosis of AKI
between the two method. As the KDIGO criteria uses baseline
KIMURA ET AL. 5 of 7
creatinine concentration for reference and the multiplication of the
baseline measurement for AKI diagnosis, low baseline creatinine con-
centration would lower the cutoff of creatinine concentration for AKI
diagnosis, such that a small error would have a big impact on the diag-
nosis of AKI. For example, a patient with a baseline creatinine concen-
tration of 0.8 mg/dL would be diagnosed as AKI stage 1 with
postoperative creatinine concentration 1.2 mg/dL. If a patient has a
baseline creatinine concentration of 0.3 mg/dL, they would be diag-
nosed as AKI stage 1 with postoperative creatinine concentration 0.45
mg/dL, which is just 0.15 mg/dL higher than the baseline value and
could easily happen due to a measurement error. In a pediatric popula-
tion where the baseline creatinine concentration is relatively low and
small variability could have a large influence on AKI diagnosis,
increased risk of errors due to multiple measurements could explain
the high AKI rate based on Cregas. Indeed, among patients with dis-
agreement on AKI diagnosis in our study, the median baseline creati-
nine level was as low as 0.29 mg/dL.
It is difficult to determine which explanation is more likely based
on our data. However, our subgroup analysis showed that the rates of
AKI diagnosis based on Cregas and Crelab were similar among patients
whose Cregas and Crelab were measured within 1 hour, along with a
high Kappa value. This finding supports both the first and the second
explanations for more patients being diagnosed with AKI based on
Cregas than based on Crelab despite the good correlation between the
two methods. Additional studies are needed to show the utility of fre-
quent creatinine measurements by POC devices for diagnosis of AKI
based on KDIGO criteria for pediatric patients.
4.4 | Limitations/generalizability
There are several limitations in this study. First, it was a retrospective
study and, thus, potentially subject to systematic error and bias. How-
ever, the clinical and electronic data were collected prospectively and
were measured independently, and the data were, therefore, not sub-
ject to unintended manipulation. Second, this was a small, single-
center study with a significant chance of a type I error and weak gen-
eralizability. Third, we used pairs of creatinine measurements for
which the time gap between measurements of Cregas and Crelab was
within 1 hour to assess the correlation and the agreement. This is
because the two samples obtained at the same time were analyzed at
different places, with an associated time gap, and because our elec-
tronic records only have information on the time of analyses, not the
time of blood sampling. Although changes in creatinine are usually
slow and unlikely to show a large difference within such a short
period, this does not reflect a perfect assessment of the accuracy of
Cregas. In addition, dramatic change in volume status during postoper-
ative period might affect our findings. Those limitations make it diffi-
cult to generalize our results. Furthermore, this study did not show
any patients' outcomes. The impact of high frequent diagnosis of AKI
by POC device on clinical outcomes remains unclear. Considering that
the cost of one blood gas measurement is about 1.2 times higher than
that of one ordinal chemistry panel in the Japanese public medical
system, the advantage of frequent creatinine measurements with the
POC device is unclear. However, it should be noted that our objec-
tives were to evaluate the POC serum creatinine measurement device
for pediatric patients and to assess the impact on diagnosis of AKI. In
this regard, a future prospective study with scheduled measurements
of Cregas and Crelab from a range of patients and evaluating clinical
outcomes should be conducted.
5 | CONCLUSIONS
There was an excellent correlation between measurements of creati-
nine by the POC blood gas analyzer and those conducted in the cen-
tral laboratory for patients who were younger than 18 years of age
and underwent cardiac surgery. Although a discordant diagnosis of
postoperative AKI based on KDIGO criteria was found in about one
third of the pediatric patients between the two methods when using
all the measurements, the paired measurements with a small time gap
showed a good agreement on AKI diagnosis. Additional studies are
needed to show the efficacy of frequent creatinine measurements by
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